Drugs in the Pipeline
Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
News
Appropriate patient selection and pharmacist-led monitoring were linked to greater adherence to dabigatran among patients with atrial fibrillation at Veterans Health Administration sites, according to a recent study published in JAMA.
Drug News
Despite trend toward lower stroke risk with high dose
News
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
News
The increased number of post-marketing reports of bleeding associated with use of dabigatran seems to be an example of stimulated reporting and may not represent an increased bleeding risk.
News
Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.
Drug News
Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.
News
The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
Drug News
Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding
Drugs in the Pipeline
Boehringer Ingelheim announced results demonstrating that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers.
